{"id":"mavenclad","safety":{"commonSideEffects":[{"rate":"~95","effect":"Lymphopenia"},{"rate":"~25","effect":"Upper respiratory tract infection"},{"rate":"~20","effect":"Headache"},{"rate":"~15","effect":"Nausea"},{"rate":"~10","effect":"Herpes zoster"},{"rate":"~5","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL1619","moleculeType":"Small molecule","molecularWeight":"285.69"},"_dailymed":{"setId":"9c75e30a-a410-40f1-b653-04d532bd9144","title":"MAVENCLAD (CLADRIBINE) TABLET [EMD SERONO, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cladribine is a deoxyadenosine analog that accumulates in lymphocytes and is phosphorylated to its active triphosphate form, which inhibits ribonucleotide reductase and disrupts DNA synthesis. This leads to selective depletion of B and T lymphocytes, reducing the autoimmune response. The drug has prolonged effects due to sustained lymphocyte depletion following short treatment courses.","oneSentence":"Mavenclad (cladribine) is a purine nucleoside analog that depletes lymphocytes by interfering with DNA synthesis and repair in dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:57.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Active secondary progressive multiple sclerosis (SPMS)"}]},"trialDetails":[{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT04695080","phase":"PHASE2, PHASE3","title":"ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-06-25","conditions":"Advanced Multiple Sclerosis, Progressive Multiple Sclerosis","enrollment":204},{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT04934800","phase":"","title":"Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2019-12-10","conditions":"Multiple Sclerosis","enrollment":256},{"nctId":"NCT04783935","phase":"PHASE4","title":"Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-03-10","conditions":"Multiple Sclerosis","enrollment":219},{"nctId":"NCT04997148","phase":"","title":"Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-08-11","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":116},{"nctId":"NCT04776213","phase":"PHASE4","title":"Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-02-23","conditions":"Multiple Sclerosis","enrollment":280},{"nctId":"NCT05902429","phase":"PHASE4","title":"Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"Pontificia Universidade Católica do Rio Grande do Sul","startDate":"2021-04-28","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":10},{"nctId":"NCT03369665","phase":"PHASE4","title":"Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-06-20","conditions":"Multiple Sclerosis","enrollment":485},{"nctId":"NCT03364036","phase":"PHASE4","title":"Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2018-05-28","conditions":"Multiple Sclerosis","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cladribine"],"phase":"marketed","status":"active","brandName":"Mavenclad®","genericName":"Mavenclad®","companyName":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","companyId":"merck-healthcare-kgaa-darmstadt-germany-an-affiliate-of-merck-kgaa-darmstadt-ger","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mavenclad (cladribine) is a purine nucleoside analog that selectively depletes lymphocytes, particularly CD4+ and CD8+ T cells and B cells, to reduce autoimmune activity. Used for Relapsing-remitting multiple sclerosis (RRMS), Active secondary progressive multiple sclerosis (SPMS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}